Targeted Cancer Therapy and Mechanisms of Resistance

Edited by
January 2022
280 pages
  • ISBN978-3-0365-2857-1 (Hardback)
  • ISBN978-3-0365-2856-4 (PDF)

This book is a reprint of the Special Issue Targeted Cancer Therapy and Mechanisms of Resistance that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology

Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called “oncogene addiction”. According to this concept, protein kinases have been identified as promising molecular targets for cancer therapy. There are several possibilities for targeting these proteins in cancer, including monoclonal antibodies, compounds able to favor the proteolytic degradation of the kinase, small-molecule protein kinase inhibitors (PKIs). Moreover, new anticancer treatments have increasingly been developed focusing on tumor suppressor genes and RNA interference. Despite promising results in cancer treatment with targeted cancer drugs, clinical experience has shown that only a fraction of patients respond to targeted therapies, even if their tumor expresses the altered target. This is known as primary resistance. Otherwise, secondary or acquired resistance to the treatment arises, almost invariably, when tumors are treated with cancer drugs. We set out to select some studies containing emerging developments on the subject. In essence, this collection aims to highlight some recent findings regarding resistance mechanisms and reviews of molecular targeting and resistance with 14 contributions, including 10 original research papers and 4 reviews. Aspects relating to solid cancers, such as breast, ovary, colon, and blood cancers such as leukemia, and the identification of resistance mechanisms and new molecular targets, help to create the basis for the preclinical and clinical development of more effective next-generation drugs.

  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
3D spheroids; photothermy; gold nanoparticles; doxorubicin resistance; colorectal cancer; cellular prion protein; PrPC; PRNP; cancer; cancer stem cell; targeted cancer therapy; brain metastases; treatment; non-small cell lung carcinoma; EGFR; ALK; immunotherapy; HDAC6; bortezomib-resistance; HDAC6-selective inhibitor; bortezomib; carfilzomib; multiple myeloma; LMP2; combination therapy; colorectal cancer cells; drug resistance; 5-Fluorouracil; thymidylate synthase; exome sequencing; CD47; immune activation; pro-tumoral macrophages; immunotherapy; breast cancer; polo-like kinase 1 (PLK1); pyrazole; quantitative structure-activity relationship; hybridization; ovarian cancer; cisplatin; cisplatin resistance; PARPi; niraparib; Twist; lethality; AF4; cell culture; FGFR2; HOXA9; MLL-AF4; nucleus; target therapy; t(4; 11) leukemia; radiation-resistant; breast cancer; cell death; ERK; EMT; cancer stem cells (CSCs); PD98059; PARP inhibitors; breast cancer; PARP inhibitor resistance; cancer; colorectal cancer; signal transduction networks; pathways; event-free survival; biomarkers; WNT pathway; targeted therapy; Wee1 kinase; cell cycle; tumor resistance; lenvatinib; sorafenib-resistant; hepatocellular carcinoma; FGFR4; autophagy; microRNA

Related Books

May 2024

Kinase Inhibitor for Cancer Therapy

Public Health & Healthcare
October 2019

Anticancer Drugs

Medicine & Pharmacology
August 2022

Anticancer Inhibitors

Medicine & Pharmacology